Skip to main content

Animations

MJFF Publications

5741 - 5750 of 8808 Results
Title
Year
  • Year
  • 2022
  • 2022
  • 2020
  • 2025
  • 2020
  • 2023
  • 2022
  • 2020
  • 2024
  • 2023
  • Summary Details
    OPEN
    Title: Use of Glycolysis‐Enhancing Drugs and Risk of Parkinson's Disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1002/mds.29184
    Citation Count: 23
  • Summary Details
    OPEN
    Title: Brain-restricted mTOR inhibition with binary pharmacology
    Journal Name: Nature
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1038/s41586-022-05213-y
    Citation Count: 60
  • Summary Details
    OPEN
    Title: Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction
    Journal Name: Nature
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1038/s41586-020-2673-2
    Citation Count: 203
  • Summary Details
    OPEN
    Title: A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer’s disease
    Journal Name: Nature Medicine
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd, cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1038/s41591-025-03565-2
    Citation Count: 19
  • Summary Details
    OPEN
    Title: Intra-striatal AAV2.retro administration leads to extensive retrograde transport in the rhesus macaque brain: implications for disease modeling and therapeutic development
    Journal Name: Scientific Reports
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1038/s41598-020-63559-7
    Citation Count: 60
  • Summary Details
    OPEN
    Title: Structure of LRRK1 and mechanisms of autoinhibition and activation
    Journal Name: Nature Structural & Molecular Biology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by, cc-by
    DOI - Digital Object Identifier: 10.1038/s41594-023-01109-1
    Citation Count: 7
  • Summary Details
    OPEN
    Title: Structural basis for Parkinson’s disease-linked LRRK2’s binding to microtubules
    Journal Name: Nature Structural & Molecular Biology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by, cc-by
    DOI - Digital Object Identifier: 10.1038/s41594-022-00863-y
    Citation Count: 47
  • Summary Details
    OPEN
    Title: MAPT haplotype–stratified GWAS reveals differential association for AD risk variants
    Journal Name: Alzheimer's & Dementia
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by, cc-by
    DOI - Digital Object Identifier: 10.1002/alz.12099
    Citation Count: 37
  • Summary Details
    OPEN
    Title: TREM1 disrupts myeloid bioenergetics and cognitive function in aging and Alzheimer disease mouse models
    Journal Name: Nature Neuroscience
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1038/s41593-024-01610-w
    Citation Count: 23
  • Summary Details
    OPEN
    Title: From policy to practice: Lessons learned from an open science funding initiative
    Journal Name: PLOS Computational Biology
    Publisher: Public Library of Science (PLoS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1371/journal.pcbi.1011626
    Citation Count: 3
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.